Policosanol

What other names is Policosanol known by?

32-C, Dotriacontanol, Heptacosanol, Hexacosanol, Nonacosanol, Octacosanol, Tetracosanol, Tétracosanol, Tetratriacontanol, Tétratriacontanol, Triacontanol.

What is Policosanol?

Policosanol is a chemical obtained from sugar cane and other sources.

Policosanol is used for many conditions, but so far, there isn't enough scientific evidence to determine whether or not it is effective for any of them.

Policosanol is used for conditions that affect the health of the heart and blood vessels including high cholesterol, leg pain due to poor circulation (intermittent claudication), and narrowing of the blood vessels that serve the heart.

Likely Effective for...

  • Leg pain due to poor blood circulation (intermittent claudication). Taking policosanol by mouth seems to improve the distance people with intermittent claudication can walk without pain.

Insufficient Evidence to Rate Effectiveness for...

  • Clogged arteries. Early research suggests that taking policosanol daily, alone or together with aspirin for 20 months, can reduce heart disease-related events in people with clogged arteries.
  • Inherited high cholesterol (familial hypercholesterolemia). Limited research suggests that taking policosanol does not reduce total cholesterol or “bad cholesterol” (low-density lipoprotein (LDL) cholesterol) in people with an inherited tendency to have high cholesterol.
  • High cholesterol. Research findings disagree about the effectiveness of policosanol in treating high cholesterol. There have been some studies that find it effective. However, all of these studies were done in Cuba, where the sugar cane that is used to make policosanol is grown. Research done outside Cuba (in Germany, Canada, and South Africa) found that policosanol does not lower cholesterol.
  • Other conditions.
More evidence is needed to rate policosanol for these uses.

SLIDESHOW

Vitamin D Deficiency: How Much Vitamin D Is Enough? See Slideshow

How does Policosanol work?

Policosanol seems to decrease cholesterol production in the liver and to increase the break down of LDL (low-density lipoprotein or "bad") cholesterol. It also decreases the stickiness of particles in the blood known as platelets, which might help reduce blood clots.

Are there safety concerns?

Policosanol is POSSIBLY SAFE for most people when taken by mouth in doses of 5-80 mg daily for up to 3 years. It can cause skin redness and rash, migraines, insomnia or drowsiness, irritability, dizziness, upset stomach, increased appetite, trouble urinating, weight loss, nose and gum bleeds, and other side effects.

Special Precautions & Warnings:

Pregnancy and breast-feeding: There is not enough reliable information about the safety of taking policosanol if you are pregnant or breast-feeding. Stay on the safe side and avoid use.

Bleeding disorders: Policosanol can slow blood clotting and might increase the chance of bleeding in people with bleeding disorders.

Surgery: Policosanol can slow blood clotting. There is a concern that it might increase the chance of extra bleeding during and after surgery. Stop using policosanol at least 2 weeks before a scheduled surgery.

Are there any interactions with medications?


Medications that slow blood clotting (Anticoagulant / Antiplatelet drugs)Interaction Rating: Major Do not take this combination.

Policosanol might slow blood clotting. Taking policosanol along with medications that also slow clotting might increase the chances of bruising and bleeding.

Some medications that slow blood clotting include aspirin, clopidogrel (Plavix), diclofenac (Voltaren, Cataflam, others), ibuprofen (Advil, Motrin, others), naproxen (Anaprox, Naprosyn, others), dalteparin (Fragmin), enoxaparin (Lovenox), heparin, warfarin (Coumadin), and others.


Medications for high blood pressure (Antihypertensive drugs)Interaction Rating: Moderate Be cautious with this combination.Talk with your health provider.

Policosanol might decrease blood pressure in some people. Taking policosanol along with medications used for lowering high blood pressure might cause your blood pressure to go too low. Do not take too much policosanol if you are taking medications for high blood pressure.

Some medications for high blood pressure include captopril (Capoten), enalapril (Vasotec), losartan (Cozaar), valsartan (Diovan), diltiazem (Cardizem), Amlodipine (Norvasc), hydrochlorothiazide (HydroDIURIL), furosemide (Lasix), and many others.

Dosing considerations for Policosanol.

The appropriate dose of policosanol depends on several factors such as the user's age, health, and several other conditions. At this time, there is not enough scientific information to determine an appropriate range of doses for policosanol. Keep in mind that natural products are not always necessarily safe and dosages can be important. Be sure to follow relevant directions on product labels and consult your pharmacist or physician or other healthcare professional before using.

CONTINUE SCROLLING FOR RELATED SLIDESHOW

Natural Medicines Comprehensive Database rates effectiveness based on scientific evidence according to the following scale: Effective, Likely Effective, Possibly Effective, Possibly Ineffective, Likely Ineffective, and Insufficient Evidence to Rate (detailed description of each of the ratings).

FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Health Solutions From Our Sponsors

Reviewed on 9/17/2019
References

Alcocer, L., Fernandez, L., Campos, E., and Mas, R. A comparative study of policosanol Versus acipimox in patients with type II hypercholesterolemia. Int.J.Tissue React. 1999;21(3):85-92. View abstract.

Aleman, C. L., Mas, R., Hernandez, C., Rodeiro, I., Cerejido, E., Noa, M., Capote, A., Menendez, R., Amor, A., Fraga, V., and . A 12-month study of policosanol oral toxicity in Sprague Dawley rats. Toxicol.Lett. 1994;70(1):77-87. View abstract.

Aleman, C. L., Puig, M. N., Elias, E. C., Ortega, C. H., Guerra, I. R., Ferreiro, R. M., and Brinis, F. Carcinogenicity of policosanol in mice: an 18-month study. Food Chem.Toxicol. 1995;33(7):573-578. View abstract.

Arruzazabala, M. L., Carbajal, D., Mas, R., Molina, V., Valdes, S., and Laguna, A. Cholesterol-lowering effects of policosanol in rabbits. Biol.Res 1994;27(3-4):205-208. View abstract.

Arruzazabala, M. L., Carbajal, D., Mas, R., Valdes, S., and Molina, V. Pharmacological Interaction Between Policosanol and Nitroprusside in Rats. J Med Food 2001;4(2):67-70. View abstract.

Arruzazabala, M. L., Molina, V., Carbajal, D., Valdes, S., and Mas, R. Effect of policosanol on cerebral ischemia in Mongolian gerbils: role of prostacyclin and thromboxane A2. Prostaglandins Leukot.Essent.Fatty Acids 1993;49(3):695-697. View abstract.

Arruzazabala, M. L., Noa, M., Menendez, R., Mas, R., Carbajal, D., Valdes, S., and Molina, V. Protective effect of policosanol on atherosclerotic lesions in rabbits with exogenous hypercholesterolemia. Braz.J Med Biol.Res 2000;33(7):835-840. View abstract.

Barocci, S., Ginevri, F., Valente, U., Torre, F., Gusmano, R., and Nocera, A. Correlation between angiotensin-converting enzyme gene insertion/deletion polymorphism and kidney graft long-term outcome in pediatric recipients: a single-center analysis. Transplantation 2-27-1999;67(4):534-538. View abstract.

Cabrera, L., Rivero, B., Magraner, J., Sierra, R., Gonzalez, V., Uribarri, E., Laguna, A., Cora, M., Tejeda, Y., Rodriguez, E., and Velazquez, C. Stability studies of tablets containing 5 mg of policosanol. Boll.Chim.Farm. 2003;142(7):277-284. View abstract.

Cabrera, L., Uribarri, E., Laguna, A., Sierra, R., Mederos, D., Gonzalez, M., and Gonzalez, V. Study of the interaction between policosanol and excipients. Boll.Chim.Farm. 2002;141(2):138-142. View abstract.

Carbajal, D., Arruzazabala, M. L., Mas, R., Molina, V., and Valdes, S. Effect of policosanol on experimental thrombosis models. Prostaglandins Leukot.Essent.Fatty Acids 1994;50(5):249-251. View abstract.

Castano, G., Mas, Ferreiro R., Fernandez, L., Gamez, R., Illnait, J., and Fernandez, C. A long-term study of policosanol in the treatment of intermittent claudication. Angiology 2001;52(2):115-125. View abstract.

Castano, G., Mas, R., Fernandez, L., Gamez, R., and Illnait, J. Effects of policosanol and lovastatin in patients with intermittent claudication: a double-blind comparative pilot study. Angiology 2003;54(1):25-38. View abstract.

Castano, G., Mas, R., Gamez, R., Fernandez, L., and Illnait, J. Effects of policosanol and ticlopidine in patients with intermittent claudication: a double-blinded pilot comparative study. Angiology 2004;55(4):361-371. View abstract.

Cholesterol-lowering action of policosanol compares well to that of pravastatin and lovastatin. Cardiovasc.J.S.Afr. 2003;14(3):161. View abstract.

Fontani, G., Maffei, D., and Lodi, L. Policosanol, reaction time and event-related potentials. Neuropsychobiology 2000;41(3):158-165. View abstract.

Gamez, R., Aleman, C. L., Mas, R., Noa, M., Rodeiro, I., Garcia, H., Hernandez, C., Menendez, R., and Aguilar, C. A 6-Month Study on the Toxicity of High Doses of Policosanol Orally Administered to Sprague-Dawley Rats. J Med Food 2001;4(2):57-65. View abstract.

Gamez, R., Maz, R., Arruzazabala, M. L., Mendoza, S., and Castano, G. Effects of concurrent therapy with policosanol and omega-3 fatty acids on lipid profile and platelet aggregation in rabbits. Drugs R.D. 2005;6(1):11-19. View abstract.

Gouni-Berthold, I. and Berthold, H. K. Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am.Heart J. 2002;143(2):356-365. View abstract.

Illnait, J., Castano, G., Alvarez, E., Fernandez, L., Mas, R., Mendoza, S., and Gamez, R. Effects of policosanol (10 mg/d) versus aspirin (100 mg/d) in patients with intermittent claudication: a 10-week, randomized, comparative study. Angiology 2008;59(3):269-277. View abstract.

Janikula, M. Policosanol: a new treatment for cardiovascular disease? Altern.Med.Rev. 2002;7(3):203-217. View abstract.

Kassis, A. N. and Jones, P. J. Changes in cholesterol kinetics following sugar cane policosanol supplementation: a randomized control trial. Lipids Health Dis 2008;7:17. View abstract.

Kassis, A. N. Evaluation of cholesterol-lowering and antioxidant properties of sugar cane policosanols in hamsters and humans. Appl Physiol Nutr Metab 2008;33(3):540-541. View abstract.

Mas, R., Castano, G., Fernandez, J., Gamez, R. R., Illnait, J., Fernandez, L., Lopez, E., Mesa, M., Alvarez, E., and Mendoza, S. Long- term effects of policosanol on older patients with Type 2 diabetes. Asia Pac.J Clin Nutr. 2004;13(Suppl):S101. View abstract.

McCarty, M. F. An ezetimibe-policosanol combination has the potential to be an OTC agent that could dramatically lower LDL cholesterol without side effects. Med Hypotheses 2005;64(3):636-645. View abstract.

McCarty, M. F. Policosanol safely down-regulates HMG-CoA reductase - potential as a component of the Esselstyn regimen. Med.Hypotheses 2002;59(3):268-279. View abstract.

Menedez, P., Prosper, F., Bueno, C., Arbona, C., San Miguel, J. F., Garcia-Conde, J., Sola, C., Hornedo, J., Cortes-Funes, H., and Orfao, A. Sequential analysis of CD34+ and. Leukemia 2001;15(3):430-439. View abstract.

Menendez, R., Amor, A. M., Gonzalez, R. M., Fraga, V., and Mas, R. Effect of policosanol on the hepatic cholesterol biosynthesis of normocholesterolemic rats. Biol.Res 1996;29(2):253-257. View abstract.

Menendez, R., Fraga, V., Amor, A. M., Gonzalez, R. M., and Mas, R. Oral administration of policosanol inhibits in vitro copper ion-induced rat lipoprotein peroxidation. Physiol Behav. 8-1-1999;67(1):1-7. View abstract.

Menendez, R., Marrero, D., Mas, R., Fernandez, I., Gonzalez, L., and Gonzalez, R. M. In vitro and in vivo study of octacosanol metabolism. Arch Med Res 2005;36(2):113-119. View abstract.

Menendez, R., Mas, R., Amor, A. M., Gonzalez, R. M., Fernandez, J. C., Rodeiro, I., Zayas, M., and Jimenez, S. Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro. Br.J.Clin.Pharmacol. 2000;50(3):255-262. View abstract.

Menendez, R., Mas, R., Amor, A. M., Ledon, N., Perez, J., Gonzalez, R. M., Rodeiro, I., Zayas, M., and Jimenez, S. Inhibition of rat lipoprotein lipid peroxidation by the oral administration of D003, a mixture of very long-chain saturated fatty acids. Can J Physiol Pharmacol. 2002;80(1):13-21. View abstract.

Mesa, A. R., Mas, R., Noa, M., Hernandez, C., Rodeiro, I., Gamez, R., Garcia, M., Capote, A., and Aleman, C. L. Toxicity of policosanol in beagle dogs: one-year study. Toxicol.Lett. 1994;73(2):81-90. View abstract.

Mirkin, A., Mas, R., Martinto, M., Boccanera, R., Robertis, A., Poudes, R., Fuster, A., Lastreto, E., Yanez, M., Irico, G., McCook, B., and Farre, A. Efficacy and tolerability of policosanol in hypercholesterolemic postmenopausal women. Int.J.Clin.Pharmacol.Res. 2001;21(1):31-41. View abstract.

Noa, M., Mas, R., and Mesa, R. A comparative study of policosanol vs lovastatin on intimal thickening in rabbit cuffed carotid artery. Pharmacol.Res 2001;43(1):31-37. View abstract.

Noa, M., Mas, R., and Mesa, R. Effect of policosanol on intimal thickening in rabbit cuffed carotid artery. Int J Cardiol 12-1-1998;67(2):125-132. View abstract.

Noa, M., Mas, R., Mendoza, S., Gamez, R., Mendoza, N., and Gonzalez, J. Policosanol prevents bone loss in ovariectomized rats. Drugs Exp.Clin Res 2004;30(3):117-123. View abstract.

Noa, M., Mendoza, S., Mas, R., and Mendoza, N. Effect of policosanol on carbon tetrachloride-induced acute liver damage in Sprague-Dawley rats. Drugs R.D. 2003;4(1):29-35. View abstract.

Ohta, Y., Ohashi, K., Matsura, T., Tokunaga, K., Kitagawa, A., and Yamada, K. Octacosanol attenuates disrupted hepatic reactive oxygen species metabolism associated with acute liver injury progression in rats intoxicated with carbon tetrachloride. J Clin Biochem Nutr 2008;42(2):118-125. View abstract.

Perez, Y., Mas, R., Gonzalez, R. M., Jimenez, S., and Molina, V. Effects of D-003, a mixture of very long chain saturated fatty acids, and policosanol on in vivo lipid peroxidation in rats. Arzneimittelforschung 2008;58(3):126-130. View abstract.

Prat, H., Roman, O., and Pino, E. [Comparative effects of policosanol and two HMG-CoA reductase inhibitors on type II hypercholesterolemia]. Rev.Med.Chil. 1999;127(3):286-294. View abstract.

Reiner, Z. and Tedeschi-Reiner, E. Rice policosanol does not have any effects on blood coagulation factors in hypercholesterolemic patients. Coll.Antropol. 2007;31(4):1061-1064. View abstract.

Rodriguez-Echenique, C., Mesa, R., Mas, R., Noa, M., Menendez, R., Gonzalez, R. M., Amor, A. M., Fraga, V., Sotolongo, V., and Laguna, A. Effects of policosanol chronically administered in male monkeys (Macaca arctoides). Food Chem.Toxicol. 1994;32(6):565-575. View abstract.

Tedeschi-Reiner, E., Reiner, Z., Romic, Z., and Ivankovic, D. [A randomized, double-blind, placebo-controlled study of the antilipemic efficacy and tolerability of food supplement policosanol in patients with moderate hypercholesterolemia]. Lijec.Vjesn. 2005;127(11-12):273-279. View abstract.

Thippeswamy, G., Sheela, M. L., and Salimath, B. P. Octacosanol isolated from Tinospora cordifolia downregulates VEGF gene expression by inhibiting nuclear translocation of NF-B and its DNA binding activity. Eur J Pharmacol 7-7-2008;588(2-3):141-150. View abstract.

Arruzazabala ML, Mas R, Molina V, et al. Effect of policosanol on platelet aggregation in type II hypercholesterolemic patients. Int J Tissue React 1998;20:119-24. View abstract.

Arruzazabala ML, Molina V, Mas R, et al. Antiplatelet effects of policosanol (20 and 40 mg/day) in healthy volunteers and dyslipidaemic patients. Clin.Exp.Pharmacol.Physiol 2002;29:891-897. View abstract.

Arruzazabala ML, Valdes S, Mas R, et al. Comparative study of policosanol, aspirin and the combination therapy policosanol-aspirin on platelet aggregation in healthy volunteers. Pharmacol Res 1997;36:293-7. View abstract.

Arruzazabala ML, Valdes S, Mas R, et al. Effect of policosanol successive dose increases on platelet aggregation in healthy volunteers. Pharmacol Res 1996;34:181-5. View abstract.

Batista J, Stusser R, Saez F, Perez B. Effect of policosanol on hyperlipidemia and coronary heart disease in middle-aged patients. A 14-month pilot study. Int J Clin Pharmacol Ther 1996;34:134-7. View abstract.

Berthold HK, Unverdorben S, Degenhardt R, et al. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial. JAMA 2006;295:2262-69. View abstract.

Canetti M, Moreira M, Mas R, et al. A two-year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinaemia. Int J Clin Pharmacol Res 1995;15:159-65. View abstract.

Carbajal D, Arruzazabala ML, Valdes S, Mas R. Effect of policosanol on platelet aggregation and serum levels of arachidonic acid metabolites in healthy volunteers. Prostaglandins Leukot Essent Fatty Acids 1998;58:61-4. View abstract.

Castano G, Canetti M, Moreira M, et al. Efficacy and tolerability of policosanol in elderly patients with type II hypercholesterolemia: A 12-month study. Curr Ther Res 1995;56:819-23.

Castano G, Fernandez L, Mas R, et al. Comparison of the efficacy, safety and tolerability of original policosanol versus other mixtures of higher aliphatic primary alcohols in patients with type II hypercholesterolemia. Int.J.Clin.Pharmacol.Res. 2002;22:55-66. View abstract.

Castano G, Fernandez L, Mas R, et al. Effects of addition of policosanol to omega-3 fatty acid therapy on the lipid profile of patients with type II hypercholesterolaemia. Drugs R.D 2005;6:207-219. View abstract.

Castano G, Mas R, Arruzazabala ML, et al. Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients. Int.J.Clin.Pharmacol.Res. 1999;19:105-116. View abstract.

Castano G, Mas R, Fernandez JC, et al. Effects of policosanol in older patients with type II hypercholesterolemia and high coronary risk. J.Gerontol.A Biol.Sci.Med.Sci. 2001;56:M186-M192. View abstract.

Castano G, Mas R, Fernandez L, et al. A comparison of the effects of D-003 and policosanol (5 and 10 mg/day) in patients with type II hypercholesterolemia: a randomized, double-blinded study. Drugs Exp Clin Res 2005;31 Suppl:31-44. View abstract.

Castano G, Mas R, Fernandez L, et al. Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia. Drugs Aging 2003;20:153-63. View abstract.

Castano G, Mas R, Fernandez L, et al. Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: a 6-month double-blind study. Int.J.Clin.Pharmacol.Res. 2001;21:43-57. View abstract.

Castano G, Mas R, Fernandez L, et al. Effects of policosanol on postmenopausal women with type II hypercholesterolemia. Gynecol.Endocrinol. 2000;14:187-195. View abstract.

Castano G, Mas R, Gamez R, et al. Concomitant use of policosanol and beta-blockers in older patients. Int J Clin Pharmacol.Res 2004;24:65-77. View abstract.

Castano G, Mas R, Roca J, et al. A double-blind, placebo-controlled study of the effects of policosanol in patients with intermittent claudication. Angiology 1999;50:123-30. View abstract.

Castano G, Menendez R, Mas R, et al. Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus. Int.J.Clin.Pharmacol.Res. 2002;22:89-99. View abstract.

Castano G, Tula L, Canetti M, et al. Effects of policosanol in hypertensive patients with type II hypercholesterolemia. Curr Ther Res 1996;57:691-5.

Castano G1, Mas R, Fernandez JC, et al. Effects of policosanol on older patients with hypertension and type II hypercholesterolaemia. Drugs R.D. 2002;3:159-172. View abstract.

Chen JT, Wesley R, Shamburek RD, et al. Meta-Analysis of natural therapies for hyperlipidemia: plant sterols and stanols versus policosanol. Pharmacotherapy 2005;25:171-83. View abstract.

Cicero, AF, Rovati LC, and Setnikar I. Eulipidemic effects of berberine administered alone or in combination with other natural cholesterol-lowering agents. A single-blind clinical investigation. Arzneimittelforschung. 2007;57:26-30. View abstract.

Crespo N, Illnait J, Mas R, et al. Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus. Int.J.Clin.Pharmacol.Res. 1999;19:117-127. View abstract.

Cubeddu LX, Cubeddu RJ, Heimowitz T, et al. Comparative lipid-lowering effects of policosanol and atorvastatin: a randomized, parallel, double-blind, placebo-controlled trial. Am Heart J 2006;152:982-985. View abstract.

Dulin MF, Hatcher LF, Sasser HC, Barringer TA. Policosanol is ineffective in the treatment of hypercholesterolemia: a randomized controlled trial. Am J Clin Nutr 2006;84:1543-1548. View abstract.

Fernandez JC, Mas R, Castano G, et al. Comparison of the efficacy, safety and tolerability of policosanol versus fluvastatin in elderly hypercholesterolaemic women. Clin Drug Invest. 2001;21:103–13.

Francini-Pesenti F, Beltramolli D, Dall'acqua S, Brocadello F. Effect of sugar cane policosanol on lipid profile in primary hypercholesterolemia. Phytother Res 2008;22:318-322. View abstract.

Francini-Pesenti F, Brocadello F, Beltramolli D, et al. Sugar cane policosanol failed to lower plasma cholesterol in primitive, diet-resistant hypercholesterolaemia: A double blind, controlled study. Complement Ther Med 2008;16:61-65. View abstract.

Golik A, Modai D, Averbukh Z, et al. Zinc metabolism in patients treated with captopril versus enalapril. Metabolism 1990;39:665-7. View abstract.

Greyling A, De Witt C, Oosthuizen W, Jerling JC. Effects of a policosanol supplement on serum lipid concentrations in hypercholesterolaemic and heterozygous familial hypercholesterolaemic subjects. Br J Nutr 2006;95:968-75. View abstract.

Kassis AN, Jones PJ. Lack of cholesterol-lowering efficacy of Cuban sugar cane policosanols in hypercholesterolemic persons. Am J Clin Nutr 2006;84:1003-8. View abstract.

Krieger D, Krieger S, Jansen O, et al. Manganese and chronic hepatic encephalopathy. Lancet 1995;346:270-4. View abstract.

Lin Y, Rudrum M, van der Wielen RP, et al. Wheat germ policosanol failed to lower plasma cholesterol in subjects with normal to mildly elevated cholesterol concentrations. Metabolism 2004;53:1309-14. View abstract.

Mas R, Castano G, Fernandez J, et al. Long-term effects of policosanol on obese patients with Type II Hypercholesterolemia. Asia Pac.J Clin Nutr. 2004;13(Suppl):S102.

Mas R, Castano G, Illnait J, et al. Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. Clin.Pharmacol.Ther. 1999;65:439-447. View abstract.

Menendez R, Arruzazabala L, Mas R, et al. Cholesterol-lowering effect of policosanol on rabbits with hypercholesterolaemia induced by a wheat starch-casein diet. Br J Nutr 1997;77:923-32. View abstract.

Menendez R, Fernandez SI, Del Rio A, et al. Policosanol inhibits cholesterol biosynthesis and enhances low density lipoprotein processing in cultured human fibroblasts. Biol Res 1994;27:199-203. View abstract.

Merck Index, 12th ed. Whitehouse Station: Merck Research Laboratories, 1996.

Moghissi KS. Risks and benefits of nutritional supplements during pregnancy. Obstet Gynecol 1981;58:68S-78S. View abstract.

Molina, Cuevas, V, Arruzazabala, M. L., Carbajal, Quintana D., Mas, Ferreiro R., and Valdes, Garcia S. Effect of policosanol on arterial blood pressure in rats. Study of the pharmacological interaction with nifedipine and propranolol. Arch Med Res 1998;29(1):21-24. View abstract.

Neal H. Dictionary of Chemical Names and Synonyms. Chelsea: Lewis Publishers, 1992.

O'Dell BL. Mineral interactions relevant to nutrient requirements. J Nutr 1989;119:1832-8. View abstract.

Ortensi G, Gladstein J, Valli H, Tesone PA. Comparative study of policosanol versus simvastatin in elderly patients with hypercholesterolemia. Cur Ther Res 1997;58:390-401.

Parker SP. ed. McGaw Hill Dictionary of Chemistry. New York: McGraw-Hill Book Company 1984.

Penland JG, Johnson PE. Dietary calcium and manganese effects on menstrual cycle symptoms. Am J Obstet Gynecol 1993;168:1417-23. View abstract.

Pons P, Rodriguez M, Robaina C, et al. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment. Int J Clin Pharmacol Res 1994;14:27-33. View abstract.

Singh DK, Li L, Porter TD. Policosanol inhibits cholesterol synthesis in hepatoma cells by activation of AMP-kinase. J Pharmacol Exp Ther 2006;318:1020-1026. View abstract.

Stusser R, Batista J, Padron R, et al. Long-term therapy with policosanol improves treadmill exercise-ECG testing performance of coronary heart disease patients. Int J Clin Pharmacol Ther 1998;36:469-73. View abstract.

Torres O, Agramonte AJ, Illnait J, et al. Treatment of hypercholesterolemia in NIDDM with policosanol. Diabetes Care 1995;18:393-7. View abstract.

Valdes S, Arruzazabala ML, Fernandez L. Effect of policosanol on platelet aggregation in healthy volunteers. Int J Clin Pharmacol Res 1996;16:67-72. View abstract.